Paper Details

  1. Home
  2. Paper Details

DNA-repair pathway inhibitors for the treatment of ovarian cancer.

Author: BryantAndrew, GaitskellKezia, HaldarKrishnayan, KehoeSean, MartinekIgor, MorrisonJo, NicumShibani

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Ovarian cancer is a major cause of cancer death in women, with most cases diagnosed at a late stage. Treatment typically involves surgery and chemotherapy with platinum-based drugs, sometimes with taxanes. While initial responses are good, most women experience a return of the cancer, requiring further chemotherapy, and eventually developing resistance to treatment. New medications that work differently than traditional chemotherapy are being developed, including those that target DNA repair. These new drugs are being compared to standard treatments to evaluate their effectiveness and side effects, aiming to improve survival and quality of life for women with advanced ovarian cancer.
Paper Details　
Original Abstract of the Article :
Ovarian cancer is the sixth most common cancer and seventh most common cause of cancer death in women world-wide.Three-quarters of women present when the disease has spread through-put the abdomen (stage III or IV) and treatment consists of a combination of debulking surgery and platinum-based chemo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/20556786

データ提供：米国国立医学図書館（NLM）

DNA-Repair Pathway Inhibitors: A New Weapon Against Ovarian Cancer

Ovarian cancer is a formidable adversary, like a desert sandstorm that can quickly spread and wreak havoc. This study explores the potential of DNA-repair pathway inhibitors, particularly PARP inhibitors, as novel therapeutic agents for ovarian cancer. The researchers are searching for new strategies to combat this challenging disease, seeking to find a potent weapon in the fight against ovarian cancer.

The study explores the role of DNA-repair pathway inhibitors in the treatment of ovarian cancer, specifically focusing on PARP inhibitors. These inhibitors work by targeting DNA repair mechanisms, potentially hindering the growth and survival of cancer cells. The researchers highlight the importance of comparing the effectiveness and side effects of these novel agents to assess their role in the treatment of advanced ovarian cancer, especially in cases where conventional chemotherapy has become ineffective.

A New Front in the War on Ovarian Cancer

This study highlights the potential of DNA-repair pathway inhibitors, particularly PARP inhibitors, as a new front in the war against ovarian cancer. The researchers emphasize the need for further research to evaluate their efficacy and safety, but these novel agents offer a promising avenue for improving treatment outcomes for patients with advanced ovarian cancer.

A New Oasis in the Desert

This research explores the potential of DNA-repair pathway inhibitors, particularly PARP inhibitors, as a new oasis in the desert of ovarian cancer treatment. The researchers highlight the importance of further research to evaluate their efficacy and safety, but these novel agents offer a promising avenue for improving treatment outcomes for patients with advanced ovarian cancer.

Dr.Camel's Conclusion

The desert of ovarian cancer can be a daunting landscape, but researchers are relentlessly seeking to find new weapons in the fight against this formidable disease. This study explores the potential of DNA-repair pathway inhibitors, particularly PARP inhibitors, offering a promising new approach to combat this challenging condition.

Date :
  1. Date Completed 2010-07-27
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

20556786

DOI: Digital Object Identifier

EMS58199

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.